Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network

Post time Half hour(s) ago

journal：Clinical Lymphoma Myeloma and Leukemia

Authors：Gabriele Gugliotta; Mario Annunziata; Isabella Capodanno; Davide Rapezzi; Immacolata Attolico; Marianna Caramella; Iolanda D. Vincelli; Antonella R. Rossi; Mario Tiribelli; Alessandra Malato; Michele Cimminiello; Vincenzo Accurso; Massimiliano Bonifacio; Sara Galimberti; Giuseppina Loglisci; Elisabetta Abruzzese; Monica Bocchia; Antonella Gozzini; Micaela Bergamaschi; Maria C. Miggiano; Agostino Tafuri; Grazia Sanpaolo; Anna R. Scortechini; Monica Crugnola; Debora Luzi; Luigiana Luciano; Gianni Binotto; Roberto Latagliata; Fausto Castagnetti; Alessandro Allegra; Giorgina Specchia; Uros Markovic; Gianantonio Rosti; Robin Foà; Giuseppe Saglio; Massimo Breccia; Fabio Stagno

Published date：2026-7-

DOI：10.1016/j.clml.2026.07.011

PDF link：https://www.sciencedirect.com/sc ... 152265026002168/pdf

Article link：https://doi.org/10.1016/j.clml.2026.07.011

Article Source：Elsevier BV。

Remark：Please provide article pdf on urgent basis

Post time 16 min. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

Post time 15 min. ago

: Waiting for confirmation
If the PDF has not been accepted after 72 hours, the system will automatically adopt it.

[Elsevier] Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network Copy

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network